A Multicenter, Randomized, Double-blind Phase III Study of PM8002 or Placebo in Combination With Nab-Paclitaxel as First-line Treatment in Inoperable Locally Advanced/Metastatic Triple-negative Breast Cancer(TNBC)

Status: Recruiting

Phase of Trial: Phase III

Latest Information Update: 17 Mar 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs PM-8002 (Primary)
Indications Liver cancer; Malignant-mesothelioma; Neuroendocrine tumours; Non-small cell lung cancer; Solid tumours; Triple negative breast cancer
Focus Registrational; Therapeutic Use
Sponsors BioNTech; Biotheus

Most Recent Events

22 Jul 2024 Status changed from not yet recruiting to recruiting.
16 Jan 2024 New trial record
09 Jan 2024 According to BioNTech media release, this trial is planned to be initiated in 2024.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight